Included in the formulation
АТХ:C.05.B.X.01 Calcium dobezilate
Pharmacodynamics:Angioprotector.Normalizes the increased permeability of the vascular wall, increases the resistance of capillaries and improves microcirculation in various vascular and metabolic diseases. Somewhat reduces the aggregation of platelets, reduces the viscosity of the blood.
Pharmacokinetics:Relatively slowly absorbed from the gastrointestinal tract. The maximum concentration in plasma (TCmax) with ingestion reaches 5-6 hours later. Binding to plasma proteins is 20-25%. Half-life is 5 hours. Does not penetrate the blood-brain barrier. In very small amounts (0.4 μg / ml after taking 1.5 g of the drug) is excreted in breast milk. It is excreted mainly by the kidneys (within 24 hours) and by the intestines.
Indications:Vascular lesions with increased fragility and permeability of capillaries (diabetic retinopathy, microangiopathy) and other disorders associated with various cardiovascular and metabolic diseases, venous insufficiency of varying severity and its consequences.
VII.H30-H36.H36.0 * Diabetic retinopathy (E10-E14 + with common fourth sign .3)
IX.I70-I79.I70.9 Generalized and unspecified atherosclerosis
IX.I70-I79.I73.0 Raynaud's syndrome
IX.I70-I79.I73.1 Obliterating thromboangitis [Berger's disease]
IX.I70-I79.I73.9 Peripheral vascular disease, unspecified
IX.I70-I79.I79.2 * Peripheral angiopathy in diseases classified elsewhere
IX.I80-I89.I80 Phlebitis and thrombophlebitis
IX.I80-I89.I87.2 Venous insufficiency (chronic) (peripheral)
Contraindications:Hypersensitivity; peptic ulcer of the stomach and duodenum in the stage of exacerbation, bleeding from gastrointestinal tract; hemorrhages caused by the use of anticoagulants; I trimester of pregnancy; kidney and liver diseases; age younger than 13 years.
Pregnancy and lactation:AT I trimester of pregnancy is contraindicated. In the second and third trimesters of pregnancy, the drug is prescribed only for vital indications if the expected effect of the application exceeds the possible risk to the fetus. When appointing during lactation, it is necessary to resolve the issue of stopping breastfeeding.
The category of FDA recommendations is not defined.
Dosing and Administration:When ingestion - 250 mg 3 times a day or 500 mg 1-2 times a day during meals for 2-3 weeks, then reduce the dose to 250-500 mg per day.In the treatment of retinopathy and microangiopathy - 250 mg 2-3 times a day for 4-6 months, then 250-500 mg per day.
Side effects:Nausea, diarrhea, vomiting; allergic reactions in the form of rash and itching; fever, chills; arthralgia; in some cases - agranulocytosis, reversible after discontinuation of the drug.
Interaction:Strengthens the effect of anticoagulants; glucocorticoids, hypoglycemic action of sulfonylurea derivatives.
Increases the antiplatelet activity of ticlopidine.
It is not recommended a combined use with lithium and methotrexate.
Special instructions:The drug can be prescribed prophylactically.
Efficacy is proven when used to treat varicose veins; for other pathologies data on clinical effectiveness is not enough.